Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in pediatric rheumatic diseases
ChiCTR2000033582Phase 4Not yet recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of golimumab in rheumatism, juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM) and 1 more (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoints: Therapy effect and Side effect. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
golimumab
03
Conditions
rheumatismjuvenile idiopathic arthritis (JIA)juvenile dermatomyositis (JDM)vasculitis
Beyond the preview
Go deeper on ChiCTR2000033582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033582.